MULTIPLE MYELOMA

Researchers explore talquetamab as a bridge therapy for multiple myeloma patients before CAR T-cell treatment, assessing safety and efficacy outcomes.

Experts explore innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges.

Jered Haddad transforms his cancer journey into a mission, cycling in Iceland to raise awareness and funds for multiple myeloma research.

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting in multiple myeloma.

FCARH143, a CAR T-cell therapy, delivered a 100% objective response rate in a phase 1 trial in patients with relapsed/refractory multiple myeloma.

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma therapy.

George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted monoclonal antibody approach.

John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and its implications for clinical practice.

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with promising efficacy and safety profiles.

Rajshekhar Chakraborty, MD, discusses the safety and tolerability of linvoseltamab with carfilzomib when used for the treatment of patients with relapsed/refractory multiple myeloma.

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing optimization.

Teclistamab shows promise for relapsed/refractory multiple myeloma patients with prior BCMA therapy, despite trends of reduced survival and response rates.

Shahzad Raza, MD, discusses the phase 2 RedirecTT-1 study which investigated the combination of talquetamab and teclistamab for treating patients with relapsed/refractory multiple myeloma complicated by extramedullary disease.

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in multiple myeloma.

George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

Innovative trispecific antibodies show promise in treating relapsed/refractory multiple myeloma and neuroendocrine carcinoma, enhancing patient outcomes and safety.

Shahzad Raza, MD, explains the rationale behind the REDIRECTT-1 study.

The FDA evaluates glofitamab and daratumumab for lymphoma and myeloma treatments, highlighting trial demographics and clinical outcomes in recent ODAC meeting.